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LETTERS TO EDITOR 
This case illustrates medication-induced 
affective psychosis in a patient with TS. 
Psychosis per se is a rare presentation in TS and 
that induced by antidepressants has not been 
documented. The antidepressant-induced manic 
psychosis was associated with worsening of 
existing tics, which is similar to previous reports 
(Berthier et al., 1998). Though clomipramine has 
been associated with exacerbation of tics (Kumar 
&Lang, 1997), emergence of new-onset coprolalia 
due to antidepressants has only been anecdotally 
cited (Delgado etal., 1990). Such an observation 
encourages further exploration of the role of 
antidepressant-induced cycling as a course 
modifier in TS. 
Another point that needs to be addressed 
is whether there is a subgroup of TS patients who 
are prone for bipolarity. A study showed that the 
risk of bipolar disorder in a group of patients with 
TS is at least four times greater than would be 
expected by chance (Kerbeshian et al., 1995). 
I The defining characteristics of this sub-group of 
patients include male adolescents who have mild 
tics and comorbid psychiatric diagnoses (Berthier 
et al., 1998). Our patient had all these 
characteristics and thus it could be argued that 
his propensity for bipolarity was unmasked by the 
antidepressant. Hence, through this report authors 
emphasize exercising caution while prescribing 
antidepressants to such patients of TS as defined 
above. This is pertinent to cases of TS with 
comorbid OCD wherein antidepressants are 
prescribed to treat the latter condition. Use of 
antidepressants with a lesser potential for causing 
a manic switch such as selective serotonin 
reuptake inhibitors or concurrent use of mood 
stabilizers can be explored in a similar situation. 
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* Correponcfence. 
RESEARCH IN INDIA: NOT GOOD ENOUGH? 
Sir, 
At the recent Mid-Term National CME of 
the Indian Psychiatric Society in Nagpur, two 
lectures caught my attention. One lecture aimed 
to provide a review of the research on 
schizophrenia from India. The review was very 
comprehensive and systematic. The speaker 
concluded that, despite the large volume of work, 
the majority of research was poor in design, had 
limited value as evidence for practice, and lacked 
originality. The second lecture, by the editor of 
this journal, was on the evidence base for the 
treatment for schizophrenia It was notable, as a 
member of the audience remarked, that not a 
single Indian study was cited in the evidence base. 
Not surprisingly, we were informed that no Indian 
study made the required mark to be considered 
as good enough evidence for the treatment of 
schizophrenia. Not a SINGLE Indian study! This 
is remarkable given that India has one of the largest 
number of psychiatrists in teaching or academic 
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positions in any developing country. The usual 
reason we hear for the lack of quality research 
from India focuses on two themes: not enough 
money, and not enough manpower. While there 
is some truth in both these allegations, I would 
suggest that the most important reason of all is 
the lack of research skills and opportunity in 
academic institutions. 
In fact, over the past few years, I have 
become aware of the enormous potential for 
original, innovative and significant research in 
psychiatry in India. The first, and most important, 
resource is the large number of trainee 
psychiatrists who must complete a research 
dissertation for their MD or DNB degrees. India is 
one of the few countries where a clinical 
psychiatric qualification requires a compulsory 
research dissertation. How many of the hundreds 
of such dissertations, however, actually involve 
innovative research? How many of these end up 
as research papers? The second major resource 
is the considerable amounts of funds being 
invested by pharmaceutical companies for drug 
trials for licencing and marketing purposes in India. 
Our society journal is filled with treatment trials, 
but yet few (if any) meet the standards required 
to be cited as evidence for practice. The reasons 
are simple to anyone who is familiar with the 
Consort Guidelines for trials(Moher, Schulz, & 
Alman 2001); virtually none of the trials meet the 
essential criteria of being randomized, controlled, 
with some efforts for masking and with an adequate 
sample size. The result: dozens of trials with very 
little evidence being generated. 
The current global attention to mental health 
in developing countries has also led to 
considerable interest in funding mental health 
research in India from international donor 
agencies. Examples of such agencies include the 
Wellcome Trust, the MacArthur Foundation and 
the PPP Foundation. Yet, many of these donors 
complain that either there are very few research 
proposals coming their way, or they are woefully 
substandard in their conception and design. Even 
when pharmaceutical companies fund research, 
many researchers simply adopt the company 
protocol; rarely is there an effort to ensure that 
the research is scientifically important. Another 
major limitation of much of the research from India 
is that it is not population based. In fact, the 
majority of research articles arise from psychiatric 
or tertiary hospital settings, in contrast to the fact 
that overwhelming majority of mental illness in our 
country is not seen in these settings. Thus, the 
context of the research is out of step with the 
epidemiological reality. Even though we constantly 
hear that treatment evidence needs to be 
generated from our setting(Patel, 2000), there is 
pitiful little quality research demonstrating this. 
The results are predictable: top psychiatric journals 
carry hardly any articles from developing countries 
and only a tiny fraction of these describe 
interventions(Patel & Sumathipaia, 2001). 
It is time that we take stock of the reality 
that Indian psychiatry is still unable to produce a 
significant impact on psychiatry as a medical and 
public health discipline both in our country and 
globally. I would argue that the single most 
important reason for this is the lack, not of 
manpower or funds, but of skills in research 
methodology. Even today, there are no formal 
training programs in research methodology in the 
vast majority of post-graduate training schemes. 
Teachers are appointed solely on the basis of their 
academic seniority, rather than academic ability. 
Thus, persons with little research training or ability 
themselves become the supervisors of MD 
dissertations of the new generation of 
psychiatrists. This problem exists overseas too, 
but schemes for research methodology are now 
becoming widespread as a means to strengthen 
the academic skills of trainees. The way forwards 
is clear: regular training schemes are essential, 
particularly in epidemiology which lies at the heart 
of medical research. The Indian Psychiatric 
Society could play a central role in this regard. It 
is impossible to expect each medical school to 
establish its own training scheme, particularly 
since many departments have only a handful of 
trainees. The IPS could provide the basis of holding 
regular epidemiology training workshops, perhaps 
one in each zone, on an annual basis. Already, 
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some pharmaceutical companies are organising 
"updates" for trainees in each zone. These 
workshops could be conducted by the many skilled 
researchers in the country, and would aim not only 
to teach research methods but also to strengthen 
inter-department research collaborative networks, 
teach how to write research proposals and to 
access funds from the growing number of donor 
agencies. Let us be hopeful that psychiatric 
research in India can capitalise on the 
considerable strengths it already has. The solution 
appear relatively straightforward. Does our Society 
have the will? 
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CORRIGENDUM 
In the article entitled, "Rabbit Syndrome- An acute 
complication of Neuroleptic Medication" , 
published in the July, 2001 issue of Indian Journal 
of Psychiatry ,the name of S.C.Bhargava co-author 
was left out inadvertently. The authors are Sujata 
Sethi & S.C.Bhargava. 
SUJATA SETHI', MD, Lecturer & S.C. BHARGAVA MD. 
Associate Professor,Department of Psychiatry, PtB.D. 
Sharma Postgraduate Institute of Medical Sciences, 
Rohtak-124001 Haryana(lndia) ('122/8, Shivaji Colony, 
Rohtak-124001 
Editor 
NOTES & NEWS 
NEW RESEARCH FUNDS AVAILABLE FOR 
TREATMENT TRIALS FOR SCHIZOPHRENIA 
AND BIPOLAR DISORDER 
The Stanley Foundation announces the 
availability of $10-$15 million per year in new 
funds specifically designated to support clinical 
trials for schizophrenia or bipolar disorder The 
Foundation will support studies on compounds in 
development, studies on the off-label use of 
existing compounds, and studies of novel and 
indigenous compounds that may be of benifit for 
these disorders. A variety of study designs will 
be considered, including adjunctive trials, 
uncontrolled pilot trials, and randomized controlled 
trials. Trials may be from single site or from multiple 
collaborating sites. A complete list of drug trials 
currently being supported by the Foundation is 
available at www Stanley research org. 
Funding for the trials may range from 
$50,000 up to $ 300,000 per year for up to three 
years depending on the design Indirect costs can 
be paid up to 15 percent as part of the total grant 
Submissions will be reviewed by a scientific 
advisory board Application can be submitted on-
line at www.stanleyresearch.org. Questions should 
be directed to Drs David Daniel, Michael Knable 
or Fuller Torrey at wilsonk @ Stanley research.org. 
Deadlines for submission of application: 
March 1 & October 1 of each year 
Stanley Foundation Research Programs 
5430 Grosvenor Lane,Suite 200,Bethesda, 
Maryland USA. 
Telephone:(301)571-0760 Fax: (301)571-0769 
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